Parkinson's Disease In The Crossfire 2011
CME Information
Earn Hours Of AMA PRA Category 1 Credit™
Research Update: Part 1 2011
1 Hour
Designation Statement
Ciné-Med, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Learning Objectives:
At the conclusion of this continuing medical education activity, participants should be able to:
- Identify the benefits and complications of levodopa
- Discuss the implications of recent studies evaluating dosing manipulations of levodopa
- Describe the Parkinson's Disease patients who are most likely to develop dyskinesias
- Explain the pros and cons of dopamine agonists
- Describe the recent information about deep brain stimulation
- Explain how gene therapy could impact treatment options available for Parkinson's Disease
Research Update: Part 2 2011
1 Hour
Designation Statement
Ciné-Med, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Learning Objectives:
At the conclusion of this continuing medical education activity, participants should be able to:
- Define the types of study designs for evaluating neuroprotection
- Identify the difficulties in evaluating neuroprotection
- Discuss the clinical implications of different patient evaluation strategies
- Identify the different agents being evaluated in ongoing neuroprotection trials
Non-Motor, Non-Dopaminergic Features 2010
1 Hour
Designation Statement
Ciné-Med, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Learning Objectives:
At the conclusion of this continuing medical education activity, participants should be able to:
- Identify the non-motor and non-dopaminergic features of Parkinson's Disease
- Identify the non-dopaminergic pathology that underlies the non-dopaminergic and non-motor features of Parkinson's Disease
- Appreciate the implication of the non-motor and non-dopaminergic features of Parkinson's Disease with respect to early diagnosis and the potential for developing a neuroprotective therapy
Experimental Therapeutics 2010
1 Hour
Designation Statement
Ciné-Med, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Learning Objectives:
At the conclusion of this continuing medical education activity, participants should be able to:
- Discuss the current status of stem cell research with regard to the treatment of Parkinson's Disease
- Explain the different types of gene therapy that are currently being explored as therapeutic options for the treatment of Parkinson's Disease
- Explain the limitations of transplantation and other cell-based therapies for Parkinson's Disease
Current Concepts in Clinical Management 2009
1 Hour
Designation Statement
Ciné-Med, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Learning Objectives:
At the conclusion of this continuing medical education activity, participants should be able to:
- Identify the motor complications associated with Parkinson’s Disease and their causes
- Explain the previous treatment options available for managing motor complications
- Discuss the positive and negative aspects of deep brain stimulation
- Explain the positive and negative outcomes associated with studies of cell-based and gene therapies for Parkinson’s Disease
- Explain the rationale for the recommendation to go directly to double-blind clinical studies
Current Concepts in Neuroprotection 2009
1 Hour
Designation Statement
Ciné-Med, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Learning Objectives:
At the conclusion of this continuing medical education activity, participants should be able to:
- Discuss the pathologic finding in transplanted fetal nigral cells in Parkinson’s Disease patients
- Define the theoretical biologic etiology of Parkinson’s Disease
- Explain the rationale for the Delayed Start protocol
- Describe the endpoints and the outcome of the ADAGIO Study
- Discuss the importance of early diagnosis in terms of effective treatment
How to get CME credit
To receive credit, participants must view the webcast or DVD, register on this site, and successfully complete the post-test and evaluation (successful passing grade ≥70%). Certificates can be printed on line.
Time to complete Activity:
1.0 hour per program.
Accreditation
These educational activities have been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Ciné-Med, Inc. and Peer Health Communications. Ciné-Med, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
Disclosure statement
Ciné-Med, Inc. in accordance with the ACCME's Standards for Commercial Support, requires individuals with control over content to disclose to learners any relevant financial relationships(s). Faculty disclosures can be found on the Faculty page.
These continuing medical education activities are jointly sponsored by Ciné-Med, Inc. and Peer Health Communications.
Commercial Support
These activities are supported by an educational grant from Teva Neuroscience.